BioTime, Inc. (BTX) Analysts See $-0.06 EPS

February 23, 2018 - By Dolores Ford

 BioTime, Inc. (BTX) Analysts See $ 0.06 EPS
Investors sentiment decreased to 1.96 in 2017 Q3. Its down 0.17, from 2.13 in 2017Q2. It fall, as 9 investors sold BioTime, Inc. shares while 15 reduced holdings. 9 funds opened positions while 38 raised stakes. 49.13 million shares or 2.79% more from 47.80 million shares in 2017Q2 were reported.
Connor Clark & Lunn Investment Management Ltd accumulated 108,650 shares or 0% of the stock. Schwab Charles Inv Management holds 0% of its portfolio in BioTime, Inc. (NYSEAMERICAN:BTX) for 105,400 shares. State Of Wisconsin Inv Board has invested 0% in BioTime, Inc. (NYSEAMERICAN:BTX). Moreover, Sg Americas Ltd Llc has 0% invested in BioTime, Inc. (NYSEAMERICAN:BTX) for 12,401 shares. Massachusetts-based State Street Corporation has invested 0% in BioTime, Inc. (NYSEAMERICAN:BTX). Iowa Bancorporation has invested 0.01% of its portfolio in BioTime, Inc. (NYSEAMERICAN:BTX). Tiaa Cref Limited Liability Co owns 183,880 shares. Ameritas Invest Prtn has 6,005 shares for 0% of their portfolio. New York-based American Int Grp Inc has invested 0% in BioTime, Inc. (NYSEAMERICAN:BTX). Huntington Bancorp holds 0% of its portfolio in BioTime, Inc. (NYSEAMERICAN:BTX) for 200 shares. Wells Fargo And Mn has 0% invested in BioTime, Inc. (NYSEAMERICAN:BTX) for 107,298 shares. Retail Bank Of Mellon Corp has invested 0% of its portfolio in BioTime, Inc. (NYSEAMERICAN:BTX). Reilly Fin Advsr Limited Liability Company holds 0% or 2,000 shares. Millennium Management Lc holds 0% in BioTime, Inc. (NYSEAMERICAN:BTX) or 14,515 shares. Veritable L P holds 108,595 shares.

Since October 13, 2017, it had 1 insider purchase, and 0 sales for $7.00 million activity.

Analysts expect BioTime, Inc. (NYSEAMERICAN:BTX) to report $-0.06 EPS on March, 15.After having $-0.05 EPS previously, BioTime, Inc.’s analysts see 20.00 % EPS growth. The stock decreased 0.38% or $0.01 during the last trading session, reaching $2.63. About 240,894 shares traded. BioTime, Inc. (NYSEAMERICAN:BTX) has risen 22.71% since February 23, 2017 and is uptrending. It has outperformed by 6.01% the S&P500.

BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies. The company has market cap of $333.66 million. The Company’s product candidates include Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV related facial lipoatrophy; OpRegen, which is in Phase I/IIa clinical trial for the treatment of the dry form of age-related macular degeneration; HyStem-BDNF, a preclinical development program for the delivery of recombinant human brain-derived neurotrophic factor directly into the stroke cavity of patients for aiding in tissue repair and functional recovery; and ReGlyde that is in preclinical development as a device for viscosupplementation and a combination product for drug delivery in osteoarthritis. It has a 6.12 P/E ratio. The firm also develops AST-OPC1, a therapy derived from pluripotent stem cells that is in a Phase I/IIa clinical trial for spinal cord injuries; AST-VAC1, a patient-specific cancer immunotherapy that is in Phase II clinical trial for acute myeloid leukemia; and AST-VAC2, a non-patient specific cancer immunotherapy, which is in Phase I/IIa clinical trial to treat non-small cell lung cancer.

More news for BioTime, Inc. (NYSEAMERICAN:BTX) were recently published by: Businesswire.com, which released: “BioTime Appoints Cavan Redmond to Its Board of Directors” on February 22, 2018. Businesswire.com‘s article titled: “and Vision Restoration Programs to Be Presented at ARVO 2018” and published on February 15, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: